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Antimicrobial peptides (AMPs), including defensins and cathelicidins, constitute an arse-
nal of innate regulators of paramount importance in the gut. The intestinal epithelium is
exposed to myriad of enteric pathogens and these endogenous peptides are essential to
fend off microbes and protect against infections. It is becoming increasingly evident that
AMPs shape the composition of the commensal microbiota and help maintain intestinal
homeostasis. They contribute to innate immunity, hence playing important functions in
health and disease. AMP expression is tightly controlled by the engagement of pattern
recognition receptors (PRRs) and their impairment is linked to abnormal host responses to
infection and inﬂammatory bowel diseases (IBD). In this review, we provide an overview
of the mucosal immune barriers and the intricate crosstalk between the host and the
microbiota during homeostasis.We focus on the AMPs and pay particular attention to how
PRRs promote their secretion in the intestine. Furthermore, we discuss their production
and main functions in three different scenarios, at steady state, throughout infection with
enteric pathogens and IBD.
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INTRODUCTION
The human gut is colonized by trillions of indigenous microor-
ganisms that constitute one of the most complex microbial
communities on earth (Backhed et al., 2005; Gill et al., 2006;
Turnbaugh et al., 2007). These microorganisms live in symbi-
otic and mutualistic relationship with the host, and thus make
up the microbiome that is essential for mediating physiology,
metabolism and host immune responses. The gut mucosa is
exposed to myriad food and microbial antigens that require differ-
ent types of responses (tolerance, suppression, or active immunity)
determined by whether the antigen is likely to be beneﬁcial or
detrimental to the host (Mowat, 2003). The gastrointestinal (GI)
tract is also a major entry point for enteric pathogens usually
co-ingested with food and the organism has developed multilevel
defense mechanisms to ﬁght against this challenge.
The intestinal mucosal surface acts as a primary barrier against
microbial invaders and toxins, whereas commensals are in a
dynamic and intimate interaction with the gut epithelium and
inﬂuence the host cellular and immune responses. Chemical bar-
riers, such as the acidic pH of the stomach and the bile ﬂuid,
provide one of the ﬁrst constitutive defenses of the GI tract. Gas-
tric ﬂuids maintain the stomach pH below 3 limiting infections
with pathogenic microbes (Tennant et al., 2008), whereas the bile,
particularly bile salts, have bactericidal functions and neutralize
enteric bacteria by speciﬁcally affecting their DNA and membrane
integrity (Begley et al., 2005). Other defense mechanisms in the
gut include mechanical and immunological barriers that protect
the organism from toxins and infections. The physical barrier is
formed by a single layer of epithelial cells covered by a stratiﬁed
layer of mucus (Figure 1). The latter is a mesh-like network of
ﬁbers composed of mucins, glycoproteins, lipids, antimicrobial
peptides (AMPs), and secretory immunoglobulin A (IgA) that
controls the passage of particular molecules (Neutra et al., 1996;
McGuckin et al., 2011) and prevents bacteria from reaching the
epithelial barrier. The mucus is constituted of two layers: a ﬁrm
epithelium-associated inner layer or glycocalyx and a viscous outer
layer (Sonnenburg et al., 2004; Kelly et al., 2007; Macfarlane and
Dillon, 2007; Linden et al., 2008). In the glycocalyx, mucins con-
tain membrane-binding domains that bind and stabilize critical
GI trophic factors potentially contributing to epithelial restitu-
tion (Corﬁeld et al., 2001). The outer layer, however, contains
soluble mucins secreted primarily by goblet cells. The thickness
of these two layers varies in each part of the GI tract and is
dependent on the presence of commensal bacteria, being thin-
ner where the microbiota is less abundant (Atuma et al., 2001;
Robbe et al., 2004). Typically, the inner mucus layer is free of
microorganisms and commensals occupy only the outer mucus
layer forming a bioﬁlm that allows their growth and prevents
their removal during peristalsis (Macfarlane and Dillon, 2007;
Johansson et al., 2008).
The intestinal epithelium tightly regulates bidirectional move-
ment of ions, nutrients and cells between the gut lumen and the
internal space (Madara, 1990). To ensure these functions and to
resist to the microbial passage, intestinal epithelial cells (IECs) are
connected to each other with tight junctions, which are formed
by integral membrane and cytoskeletal anchor proteins (Shen
and Turner, 2006). Moreover, IECs sense microbial-associated
molecular patterns (MAMPs), shared between commensals and
pathogens, through pattern recognition receptors (PRRs) includ-
ing Toll-like receptors (TLRs) and NOD-like receptors (NLRs),
and elaborate a microorganism-dependent program of intestinal
homeostasis and repair (Lavelle et al., 2010; Takeuchi and Akira,
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FIGURE 1 | Intestinal mucosal surface at the steady state.The intestinal
epithelial barrier is a highly organized mucosal surface that prevents the entry
of microbes into the lamina propria. The epithelium is constituted of a single
layer of intestinal epithelial cells (IECs) covered by a stratiﬁed mucus layer.
Unlike the outer mucus layer that is colonized by commensal species, the
inner mucus layer is mostly devoid of bacteria; it contains Immunoglobulin A
(IgA) and antimicrobial peptides (AMPs) that avert the commensal species
from interacting with the surface of the IECs. Yet, few opportunistic bacteria
such as segmented ﬁlamentous bacteria (SFB) can breach the mucus barrier
and enter in contact with the IECs. There are ﬁve IEC lineages derived from
epithelial stem cells that proliferate and give rise to daughter cells. These cells
include enterocytes, mucus-producing goblet cells, hormone-producing
enteroendocrine cells, AMP-producing Paneth cells at the base of the crypts
and ﬁnally, M cells that sample antigens from the intestinal lumen in order to
present them to nearby immune cells. A high number ofT cells, macrophages,
IgA secreting B and plasma cells are present in the lamina propria and the
Peyer’s patches. In addition, CD103+CD11b− and CD103+CD11b+ dendritic
cells (DCs) promote the development ofT helper (Th17) andT regulatory (Treg)
cells respectively, while CX3CR1+ DCs sample the lumen antigenic
content.
2010; Yeretssian, 2012). This promotes proliferation of epithelial
cells, secretion of IgA into the gut lumen and expression of innate
immune effector molecules, namely AMPs that likewise have a key
homeostatic role in shaping the composition of the microbiota
(Salzman et al., 2010). Every immune barrier in the gut contains an
array of immune cells that patrol the physical barrier and regulate
tissue immunity. Thus, the innate and adaptive immune systems
build an additional defense line essential to eliminate microbiota
that have bypassed earlier barriers. Enteric pathogens have evolved
strategies to either inﬁltrate or evade the secreted and cellular bar-
riers to infections. Otherwise, defects in the functions of these
mucosal barriers alter the gut ecosystem and the microbes gain
the potential to invade the host and can lead to intestinal disor-
ders such as inﬂammatory bowel diseases (IBDs; Sartor, 2008) and
irritable bowel syndrome (Parkes et al., 2008), obesity (Ley et al.,
2006), diabetes (Wen et al., 2008), etc.
In this review,we describe recent advances in the central emerg-
ing role of AMPs in the GI tract. We provide an overview on the
dynamic yet intricate interactions between the intestinal epithe-
lial barrier and the lumen microorganisms both commensals
and enteric pathogens. We further discuss how innate immune
PRRs regulate AMP production during homeostasis, infection,
and IBDs.
MUCOSAL IMMUNE BARRIER AND HOMEOSTASIS
Intestinal homeostasis relies on a tightly regulated crosstalk
between commensal bacteria, IECs, and mucosal immune cells.
The intestinal epithelium is composed of ﬁve cell lineages that
include goblet cells, Paneth cells, microfold (M) cells, enteroen-
docrine cells, and absorptive enterocytes that arise from a
pluripotent stem cell progenitor and contribute to barrier integrity
through unique and specialized mechanisms (Garrett et al., 2010;
Figure 1). Intestinal epithelial stem cells proliferate and then
differentiate into villous and colonic enterocytes that ensure
nutrient adsorption and AMP secretion (Karam, 1999; Bjerknes
and Cheng, 2006). Likewise, progenitor IECs differentiate into
mucus-secreting goblet cells (Karam, 1999), hormone-producing
enteroendocrine cells (Schonhoff et al., 2004), and at the base of
the small intestinal crypt, into Paneth cells that produce various
AMPs (van Es et al., 2005; Bjerknes and Cheng, 2006). M cells
are specialized epithelial cells of the small intestine; together with
follicle-associated epithelial cells they overlie the Peyer’s patches
and play a major role in sampling the intestinal lumen and
presenting its content to nearby immune cells (Miller et al., 2007).
In steady state, the lamina propria and the gut-associated lym-
phoid tissue (GALT) comprise a large number of T lymphocytes in
equal abundance to plasma cells that produce IgA, and also contain
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macrophages and dendritic cells (DCs; MacDonald and Mon-
teleone, 2005). The complexity of the intestinal mucosal surface
is well illustrated by the diversity of cells issued from the lym-
phoid lineage and the array of cytokines secreted from these cells
(Macpherson andHarris, 2004; Cheroutre et al., 2011). In response
to lumen antigens, a high fraction of these lymphocytes produce
polarized cytokines such as interleukin (IL)-5, IL-13, IL-17, IL-
22, and/or interferon (IFN)-γ, which are extensively reduced in
germ-free (GF) animals (Hall et al., 2008; Ivanov et al., 2008).
The characteristics, functions, and expression of cytokines within
the intestine have been recently reviewed (Spits and Di Santo,
2011; Pearson et al., 2012). GF mice exhibit underdeveloped lym-
phoid tissues with fewer Peyer’s patches, aberrant development
and maturation of isolated lymphoid follicles, reduced expres-
sion of several AMPs, lower numbers of ﬂora-reactive B cells and
lamina propria CD4+ T cells; this particularly affects the fre-
quencies of T helper (Th1 and Th17) cells but not regulatory
T (Treg) cells (Hooper et al., 2003; Mazmanian et al., 2005; Cash
et al., 2006; Bouskra et al., 2008; Hall et al., 2008; Ivanov et al.,
2008; Hapfelmeier et al., 2010). Interestingly, these defects can
be adjusted by colonization of the mice with a complex micro-
biota or speciﬁc bacterial species that orchestrates T cell responses
(Talham et al., 1999; Umesaki et al., 1999; Heczko et al., 2000;
Gaboriau-Routhiau et al., 2009; Ivanov et al., 2009). Examples of
these speciﬁc bacterial species include the segmented ﬁlamentous
bacteria (SFB) and Clostridium species. Colonization of GF mice
with SFB enhances the differentiation of Th17 cells, which are
required for host resistance against enteric pathogens and drive
systemic autoimmunity (Gaboriau-Routhiau et al., 2009; Ivanov
et al., 2009; Wu et al., 2010). Proinﬂammatory Th17 cells are
the most abundant cellular source for IL-17 and IL-22 cytokines
and they are kept in check by the actions of IL-10 producing
lamina propria Treg cells critical for the maintenance of intesti-
nal homeostasis. Indeed, capsular polysaccharide A from the
human symbiont Bacteroides fragilis beneﬁcially inﬂuences the gut
immune response by facilitating Foxp3+ Treg differentiation and
IL-10 production during commensal colonization (Mazmanian
et al., 2008; Round and Mazmanian, 2010). Furthermore, colo-
nization of GF mice with a mix of Clostridium strains provided an
environment rich in transforming-growth factor-β (TGF-β) and
promoted Foxp3+ Treg cell accumulation and activity in the colon
(Atarashi et al., 2011).
Specialized subsets of DCs and macrophages are also present
in healthy lamina propria and they differentially induce Th17 and
Treg cell responses (Denning et al., 2007; Figure 1). Macrophages
display an anti-inﬂammatory proﬁle but are fully capable of
killing bacteria whereas DCs are basically proinﬂammatory (Kel-
sall, 2008). DCs can be divided into two main populations
based on the expression of CX3CR1 (CX3C chemokine recep-
tor 1) and CD103 (αE integrin) both of which promise the
ability of DCs to control the type and extent of T cell activa-
tion (Denning et al., 2007; Schulz et al., 2009; Niess and Adler,
2010). CX3CR1+ DCs can sense and sample the intestinal lumen
through protrusions across the epithelial barrier and their expan-
sion seems to depend on the presence of microbiota (Niess et al.,
2005; Niess and Adler, 2010). Indeed, CX3CR1+ DCs help Th17
cell differentiation (Denning et al., 2007; Atarashi et al., 2008;
Uematsu et al., 2008); however a fraction of these cells contribute
to the expansion of Foxp3+ Treg cells during oral tolerance (Hadis
et al., 2011). CD103+ DCs express high levels of retinoic acid and
TGF-β that together favor the induction of Foxp3+ Treg cells and
drive the differentiation of tolerogenic DCs (Coombes et al., 2007;
Sun et al., 2007; Iliev et al., 2009). While immune cells are essential
to conserve the balance at the gut mucosal surface, AMPs have a
major role in reinforcing this barrier.
INTESTINAL AMPs AND HOMEOSTASIS
Innate immunity provides the ﬁrst line of defense against invading
microorganisms and confers protection by triggering inﬂamma-
tory and antimicrobial responses. PRRs and AMPs are evolution-
arily conserved effector molecules of the innate immune system
within the gut. They help increase IEC potential to avert bacterial
uptake, a critical process for maintaining a functional gut immune
barrier and homeostasis. The expression of AMPs is tightly regu-
lated by the presence of microorganisms via different mechanisms
mainly implicating the activation of PRRs (TLRs and NLRs) in
IECs (Cash et al., 2006). Among the various AMPs produced in
the GI tract, defensins and cathelicidins constitute the two major
classes. Likewise, IECs secrete slightly larger AMP molecules with
comparable bactericidal activities.
DEFENSINS
Defensins are small, cationic peptides containing disulﬁde bonds
necessary to damage the bacterial cell membrane and eradicate
bacteria (Ganz, 2003). These small peptides are further classi-
ﬁed as α- and β-defensins depending on the position of their
disulﬁde bonds (Ganz, 2003). The α-defensins (also called crypt-
dins in mice) comprise four human neutrophil peptides (HNPs
1–4) present in neutrophils and two human α-defensins (HD-5
and HD-6) that are mainly made by Paneth cells, with signiﬁ-
cantly lower expression in the colon than in the small intestine
(Porter et al., 2002; Ganz, 2003). Interestingly, HD-5 has the
ability like lectins to bind to glycosylated proteins and neu-
tralize bacterial exotoxins (Lehrer et al., 2009). Mice encode 19
cryptdins and six cryptdin-related sequence (CRS) peptides in
a single 1-Mb locus with high heterogeneity between mouse
strains (Ouellette, 2006; Shanahan et al., 2011). Synthesis of these
peptides is mainly limited to Paneth cells of the small intes-
tine. The α-defensins are accumulated in secretory granules of
Paneth cells as inactive pro-peptides and need proteolytic cleav-
age in order to gain antimicrobial activity (Ouellette, 2006).
Cryptdins are activated by matrix metalloproteinase 7 (MMP7)
within the granules, while HD-5 and HD-6 are processed by
trypsin after their release (Ghosh et al., 2002; Porter et al., 2002;
Shirafuji et al., 2003). Compared to α-defensins, the relative
expression level of β-defensins is more variable throughout the
GI tract. Both humans and mice express quite a large num-
ber of β-defensins, of which six human β-defensins (hBDs) and
ﬁve mouse β-defensins (mBDs) have been identiﬁed and char-
acterized. β-Defensins are expressed by many types of epithelial
cells, including enterocytes (O’Neil et al., 1999; Frye et al., 2000).
The hBD1 and its ortholog mBD1 are constitutively expressed
within the GI tract and mostly remain stable during inﬂamma-
tion, while hBD2, hBD3, and hBD4 are induced upon pathogen
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encounter (O’Neil et al., 1999; Krisanaprakornkit et al., 2000;
Takahashi et al., 2001).
In addition to their antimicrobial properties against both
Gram-negative and Gram-positive bacteria, defensins promote
inﬂammatory innate and adaptive immune reactions and pos-
sess effective chemo-attractant activities (Yang et al., 1999). These
mediators are known to recruit and activate different leuko-
cyte populations (Oppenheim and Yang, 2005). Among the
β-defensins, hBD1–3 and mBD2/3 show chemotactic activity
toward immature DCs and memory T cells (Yang et al., 1999).
Furthermore, hBD2 is able to induce recruitment of neutrophils
and mast cells (Niyonsaba et al., 2002, 2004). HNPs also con-
tribute to adaptive immunity by selectively mobilizing naïve T
cells and immature DCs (Yang et al., 2000). HNP1 and HNP2 have
been described to attract monocytes (Territo et al., 1989), while
HNP1, HNP3, and HD-5 are responsible for the chemoattrac-
tion of macrophages and memory T cells (Grigat et al., 2007).
Interestingly, some defensins, such as hBD2, have the ability to
directly bind to the CC-chemokine receptors CCR6 and CCR2,
andarebelieved to act as“micro-chemokines”capable of recruiting
leukocytes to sites of microbial invasion (Yang et al., 1999; Rohrl
et al., 2010). Structurally, hBD2 can be considered as a simpliﬁed
form of murine CCL20. HBD2 bares aspartic acid and leucine
residues placed in similar position and orientation as those in the
DCCL motif of CCL20 that provides the interaction with CCR6
receptor (Perez-Canadillas et al., 2001). Thus far, the receptors for
α-defensins have not been identiﬁed, but it has been suggested that
HNPs use Giα protein-coupled receptors since their chemotactic
effect is blocked by pertussis toxin (Yang et al., 2000).
Besides their role as chemotactic effectors, defensins modulate
the maturation and differentiation of leukocytes. The α-defensins
HNP1–3 control thematurationof humanmonocyte-derivedDCs
and depending on the dose can up-regulate or down-regulate the
maturation of these cells (Rodriguez-Garcia et al., 2009). HBD3
induces the expression of the costimulatory molecules CD80,
CD86, and CD40 on myeloid DCs and monocytes through TLR1
and TLR2 (Funderburg et al., 2007), whereas mBD2 induces the
activation of DCs in a TLR4-dependent manner (Biragyn et al.,
2002). Furthermore, mBD14 is able to switch naïve T cells into
a regulatory phenotype by inducing the expression of Foxp3 and
cytotoxic T-lymphocyte antigen 4 (CTLA-4; Navid et al., 2012).
Finally, both HNP1 and hBD1 were shown to be chemotactic
for monocyte-derived DCs, they induce the activation of these
cells and enhance the induction of pro-inﬂammatory mediators
(Presicce et al., 2009).
CATHELICIDINS
Cathelicidins constitute another major class of AMPs expressed
on the top of colonic crypts (Hase et al., 2002). In humans and
mice only one cathelicidin was identiﬁed, LL-37/hCAP18 and
CRAMP, respectively. LL-37 is a small and linear peptide charac-
terized by a highly conserved N-terminal structure named cathelin
(cathepsin L inhibitor), and a variable C-terminal cationic domain
that exerts microbicidal effect (Mendez-Samperio, 2010). It pos-
sesses a broad bactericidal activity toward both Gram-negative
and Gram-positive bacteria (Turner et al., 1998). LL-37 neutral-
izes lipopolysaccharide (LPS), it has synergistic antibacterial effects
with the defensins and presents chemotactic activity for neu-
trophils, monocytes, and T cells (Agerberth et al., 2000; De et al.,
2000; Nagaoka et al., 2000). Similarly to defensins, LL-37 bind-
ing to microbes is driven by electrostatic interactions leading to
aqueous pore formation at the surface of bacteria and their sub-
sequent lysis (Herce and Garcia, 2007; Mendez-Samperio, 2010;
Sochacki et al., 2011). In addition to its microbicidal activity, it was
described that LL-37 interacts with the formyl peptide receptor-
like 1 (FPRL-1) and through this interaction contributes to innate
and adaptive immunity by recruiting granulocytes, monocytes,
and T cells to sites of microbial invasion (Agerberth et al., 2000;
De et al., 2000).
OTHER INTESTINAL ANTIMICROBIALS
Antimicrobial C-type lectins have recently been identiﬁed in
human and mouse Paneth cells (Lasserre et al., 1999; Vaishnava
et al., 2008). These proteins simply consist of a carbohydrate
recognition domain and a N-terminal signal peptide (Iovanna
and Dagorn, 2005). The main human lectin is the regener-
ating islet-derived protein 3-alpha (RegIIIα), also known as
hepatocarcinoma-intestine-pancreas/pancreatic-associated pro-
tein (HIP/PAP). The mouse ortholog of human RegIIIα is
RegIIIγ (Cash et al., 2006). Following proteolytic activation by
trypsin, both lectins exert antimicrobial actions against Gram-
positive bacteria through binding to peptidoglycan (Medveczky
et al., 2009; Mukherjee et al., 2009; Lehotzky et al., 2010). Unlike
other AMPs, the C-type lectins are induced within the intes-
tine in a TLR/MyD88 (myeloid differentiation primary respon-
se protein 88)-dependent manner (Cash et al., 2006; Vaishnava
et al., 2008).
Various intestinal enzymes such as lysozyme C, secretory phos-
pholipase A2 type IIA (sPLA2) and angiogenin 4 (ANG4) have
also been shown to play antimicrobial functions. In humans,
lysozyme C is expressed in Paneth cells and abundant in vari-
ous cell secretions, whereas in mice it is encoded by two separate
genes, one expressed in macrophages (lysozyme C type M) and
the other in Paneth cells (lysozyme C type P; Cross et al., 1988;
Ganz, 2004). Lysozyme C is a glycoside hydrolase that damages
Gram-positive bacterial cell walls by cleaving peptidoglycan and
rendering bacteria susceptible to disruption by osmotic pressure
(Masschalck and Michiels, 2003). sPLA2 is another important
antibacterial gene constitutively expressed by Paneth cells and
found to rapidly degrade bacterial phospholipids, thereby destroy-
ing cell integrity (Qu et al., 1996; Lambeau and Gelb, 2008). In
addition to a strong activity against a wide range of bacteria,
sPLA2has pro-inﬂammatory properties andpossibly confers resis-
tance to intestinal tumorigenesis (Cormier et al., 1997; Bidgood
et al., 2000; Buckland and Wilton, 2000). ANG4 is an angiogenic
protein secreted by mouse Paneth cells into the gut lumen and
belongs to a family of RNases with antibacterial and antiviral func-
tions (Hooper et al., 2003; Crabtree et al., 2007). Colonization of
GF-mice with conventional microbiota or speciﬁcally with Bac-
teroides thetaiotaomicron enhances the production of ANG4 by
Paneth cells (Hooper et al., 2003). This enzyme retains ribonucle-
ase activity that makes it effective against various Gram-positive
and Gram-negative microorganisms (Stappenbeck et al., 2002;
Crabtree et al., 2007). In direct contact with the microbiota, IECs
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produce antimicrobial proteins with cationic properties includ-
ing the bactericidal/permeability-increasing protein (BPI) and a
variety of chemokines of which CCL20 (also known as MIP-3α;
Izadpanah et al., 2001; Canny et al., 2002). In order to control
inﬂammation in the GI tract and eliminate bacteria, BPI has
the ability to bind to LPS and neutralize its activity, whereas
CCL20 is a potent chemotactic agent for T cell and DC sub-
sets (Elsbach et al., 1994; Izadpanah et al., 2001; Canny et al.,
2002; Yang et al., 2003). Moreover, CCL20 possesses strong bac-
tericidal activity, in some cases of greater potency than hBDs
(Hoover et al., 2002). Resistin-like molecule β (RELMβ) is an
effector molecule produced by goblet cells and involved in main-
taining intestinal epithelium barrier function by up-regulating
mucin gene expression and preventing bacterial penetration. It
is believed that the presence of the microbiota is associated with
the production of RELMβ (Artis et al., 2004; Hogan et al., 2006).
The expression of AMPs and other molecules with antimicrobial
properties in the gut reveal a mechanism whereby intestinal com-
mensal bacteria inﬂuence gut microbial ecology and shape innate
immunity.
PRRs IN PROMOTING AMP SECRETION
It is expected that indiscriminate recognition of MAMPs by TLRs
and NLRs on the epithelium would trigger an inﬂammatory
response via nuclear factor-κB (NF-κB) activation and subse-
quent pro-inﬂammatory cytokine/chemokine and AMP produc-
tion (Kawai and Akira, 2011; Figure 2). However, the epithelium
seems to tolerate the presence of commensals. Inﬂammation only
occurs after disruption of the epithelial barrier and activation
of TLRs and NLRs by commensals is fundamental for protec-
tion against injury (Rakoff-Nahoum et al., 2004; Yeretssian, 2012).
TLRs are expressed by IECs with relatively low but inducible lev-
els throughout infection or intestinal inﬂammation (Otte et al.,
2004; Kawai and Akira, 2011). The spatial distribution of TLRs
in the epithelium, their cell lineage speciﬁcity and functions
within the gut were reviewed elsewhere (Abreu, 2010). NLRs are
cytosolic PRRs related to disease resistance R proteins in plants
and to apoptosis protease activating factor 1 (APAF1; Inohara
et al., 1999; Belkhadir et al., 2004). Among the NLRs, NOD1
and NOD2 induce proinﬂammatory and antimicrobial gene tran-
scription through NF-κB and mitogen-activated protein kinase
(MAPK) pathways (Chamaillard et al., 2003; Girardin et al., 2003;
Inohara et al., 2003; Figure 2). Recent advances in the ﬁeld have
linked several apoptosis effectors such as cIAP1 and cIAP2 (cel-
lular inhibitor of apoptosis proteins 1 and 2) as well as BID
(BH3 interacting-domain death agonist) to NOD signaling at
the mucosal surface, extending further the mounting parallel
between cell death and innate immunity pathways (Bertrand et al.,
2009; Yeretssian et al., 2011). NOD1 is constitutively expressed
in IECs, while NOD2 expression is conﬁned to Paneth cells in
the small intestine. Other members of the NLR family such as
NLRC4, NLRP3, NLRP6, and NLRP12 activate macromolecu-
lar complexes termed inﬂammasomes through recruitment and
activation of the proinﬂammatory caspase-1 and subsequent mat-
uration of IL-1β and IL-18 (Yeretssian, 2012; Figure 2). The
majority of these inﬂammasome-activating NLRs are expressed
in IECs and they contribute in the steady state regulation of the
commensal microﬂora through the induction of a basal secretion
of IL-18 by the IECs. Recently, it was reported that deﬁcien-
cies in the NLR/Caspase-1/IL-18 pathways are associated with a
more severe phenotype in mouse models of acute dextran-sulfate
sodium (DSS) colitis, possibly mediated, in part, by a defect in
microbiota composition and in mucosal tissue repair (Allen et al.,
2010, 2012b; Dupaul-Chicoine et al., 2010; Salcedo et al., 2010;
Zaki et al., 2010, 2011; Elinav et al., 2011).
Accumulating evidence suggests that TLRs in Paneth cells
tightly regulate AMP production via their adaptor molecule
MyD88 in the prospect to maintain a healthy gut environment.
Transgenic mice expressing a dominant-negative mutant form
of MyD88 (dnMyD88) and mice lacking MyD88 had decreased
Paneth cell-derived α-defensins (cryptdins), RegIIIβ, RegIIIγ,
and RELMβ (Brandl et al., 2007; Rakoff-Nahoum and Medzhi-
tov, 2007; Vaishnava et al., 2008; Gong et al., 2010). Indeed,
aged dnMyD88 transgenic mice develop spontaneous intestinal
inﬂammation due to a drop in AMP secretion and continu-
ous bacterial translocation (Gong et al., 2010). AMP production
is also inducible in a TLR-dependent manner in response to
a wide range of TLR agonists. For instance, in vivo stimu-
lation of TLR3 and TLR9 with polyinosinic:polycytidylic acid
(poly I:C) and CpG oligodeoxynucleotides (CpG-ODN), respec-
tively, triggers rapid Paneth cell degranulation and release of
high quantity of AMPs (Rumio et al., 2012; Figure 2). It has
been shown that hBD2 is up-regulated in IECs following TLR2,
TLR3, andTLR4 engagement and in anNF-κB-dependentmanner
(Vora et al., 2004; Omagari et al., 2011). Besides, AMP secre-
tion in the gut is not solely exclusive to Paneth cells. It was
proposed that hormone producer enteroendocrine cells sense
luminal bacterial antigens through TLR4, TLR5, and TLR9, and
neutralize intestinal bacteria by releasing chemokines and hBD2
(Palazzo et al., 2007).
NOD-like receptors turn out to act equally as key gatekeepers
in the gut and disrupted expression of these receptors is asso-
ciated with an altered expression of AMPs. Unlike MyD88−/−
mice,Nod2−/− micepresent normal levels of RegIIIβ, RegIIIγ, and
RELMβ (Abe et al., 2006; Vaishnava et al., 2008; Figure 2). How-
ever, the expression of α-defensins is signiﬁcantly reduced in these
mice. It was described that Nod2−/− mice harbor an increased
load of commensal resident bacteria compared to wild-type mice
and that they have a diminished ability to prevent intestinal col-
onization by pathogenic bacteria (Petnicki-Ocwieja et al., 2009;
Rehman et al., 2011). Under speciﬁc pathogen free conditions,
Nod1−/−Nod2−/− mice had lower RegIIIγ expression compared
to their littermate controls (Natividad et al., 2011). These mice
were more susceptibility to DSS-induced colitis; a phenotype that
was reversed by colonization of the mice with altered Schaedler
ﬂora or Biﬁdobacterium breve and that normalized RegIIIγ expres-
sion levels. Likewise, NLRP3 and NLRP6 inﬂammasomes are
major regulators of intestinal homeostasis (Elinav et al., 2011;
Hirota et al., 2011). In fact, Nlrp3−/− mice display altered colonic
mBD1 expression and a unique intestinal microbiota compared
to wild-type animals (Hirota et al., 2011). Nlrp6−/− mice on
the other hand show a radical change in microbial community
composition prominent to the expansion of colitogenic bacteria
and shifting the balance toward a pro-inﬂammatory conﬁguration
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FIGURE 2 | Regulation of AMP secretion byTLRs and NLRs during
homeostasis and infection. AMPs, mainly secreted by enterocytes and
Paneth cells, are found in the inner mucus layer and play important roles
in the barrier against enteric pathogens. At the steady state, microbial-
associated molecular patterns, (MAMPs, green stars) from commensal
bacteria are sensed by pattern recognition receptors (PRRs). They trigger
basal AMP and interleukin-18 (IL-18) production through the activation of
NF-κB and inﬂammasome pathways, respectively. This participates in the
tuning of host responses toward tolerance and help maintaining intestinal
homeostasis. Loss of homeostasis occurs when pathogens breach the
mucus layer, enter in contact with IECs and disrupt the epithelial barrier
integrity. Pathogens and their products (MAMPs, red stars) are also sensed
by PRRs and induce MyD88- or inﬂammasome-dependent expression of a
pro-inﬂammatory and antimicrobial program. In consequence, high
levels of AMPs and cytokines/chemokines are produced that help limit
pathogen propagation and contribute to the recruitment of immune cells.
hBD, human β-defensin; mBD, mouse β-defensin; HD, human
α-defensin.
that drives spontaneous and induced colitis (Elinav et al., 2011).
Microbicidal and chemotactic activities of AMPs require different
concentrations of a particular molecule and may be relevant in
different situations during infection and disease.
AMP PRODUCTION IN RESPONSE TO ENTERIC
BACTERIAL PATHOGENS
Despite the presence of multilayered innate defense barriers and
basal physiological and protective inﬂammation, enteric bacte-
rial pathogens can efﬁciently circumvent these barriers, infect
and multiply within the gut mucosa. Enteric pathogens such as
Salmonella spp., Shigella spp., Listeria spp., Citrobacter rodentium,
enteropathogenic Escherichia coli (EPEC), and enterohemorrhagic
E. coli (EHEC) subvert the microbiota through highly sophis-
ticated and effective strategies; particularly by diverting AMP
production (Figure 2). Infection with these pathogens accounts
for signiﬁcant morbidity and mortality worldwide and causes
outbreaks in developed countries.
Enteropathogenic E. coli and EHEC are human diarrheal
pathogens poorly pathogenic in mice (Guttman et al., 2006).
C. rodentium serves as an excellent surrogate model for study-
ing EPEC and EHEC pathogenesis in mice (Mundy et al., 2005).
These bacteria use attaching and effacing (A/E) lesion formation
as a major mechanism of tissue targeting and infection. In vitro
experiments using Caco-2 IECs have shown that EPEC infec-
tion promotes a rapid induction of hBD2 and CCL20 as well as
other proinﬂammatory molecules in a type three-secretion system
(TTSS)-dependent manner (Khan et al., 2008; Table 1). Addition-
ally, HT-29 human colonocytes depleted from NOD2 and infected
with C. rodentium exhibited diminished levels of hBD2 (LeBlanc
et al., 2008). C. rodentium as many other enteric pathogens has the
ability to takeover host-signaling and modulate innate and adap-
tive immune responses at epithelial surfaces. Wild-type C57BL/6
mice infected with C. rodentium up-regulated mBD1 and mBD3
in the colonic tissue (Simmons et al., 2002). Similarly, enterocytes
from mice lacking caspase-12, an endogenous inhibitor of the
inﬂammasome and NF-κB pathways, hyper-produced mBD1 and
a subset of chemokines in a NOD2-dependent manner (LeBlanc
et al., 2008). Interestingly, Nod2−/− mice are more susceptible to
C. rodentium infection and present a delayed bacterial clearance
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Table 1 | Human and mouse intestinal antimicrobial peptides and their expression during infection and intestinal inflammation.
Class Name Specie Producing cells Expression during
infection
Reference
α-Defensins HD-5, HD-6 H.s. Paneth cells Salmonella↑
CD↓
UC↑
Porter et al. (2002), Fahlgren et al. (2003),
Ganz (2003), Wehkamp et al. (2004)
Cryptdin M.m. Paneth cells S. typhimurium↑ Salzman et al. (2003), Shanahan et al. (2011)
CRS M.m. Paneth cells – Shanahan et al. (2011)
β-Defensins hBD1 H.s. Enterocytes Shigella↓
CD↓
UC↓
O’Neil et al. (1999), Islam et al. (2001),
Wehkamp et al. (2003)
hBD2 H.s. Enterocytes EPEC↑
S. typhimurium↑
UC↑
CD
O’Neil et al. (1999), Ogushi et al. (2001),
Fahlgren et al. (2003), Khan et al. (2008),
Langhorst et al. (2009)
hBD3, hBD4 H.s. Enterocytes Shigella O’Neil et al. (1999), Sperandio et al. (2008)
hBD5, hBD6 H.s. Enterocytes – O’Neil et al. (1999)
mBD1 M.m Enterocytes C. rodentium↑ O’Neil et al. (1999), Simmons et al. (2002),
Rehman et al. (2011)
mBD3 M.m. Enterocytes C. rodentium↑
DSS↓
O’Neil et al. (1999), Simmons et al. (2002),
Rehman et al. (2011)
mBD2, mBD4,
mBD5
M.m. Enterocytes – O’Neil et al. (1999)
Cathelicidins LL-37/hCAP18 H.s. IECs Shigella
UC↑
Islam et al. (2001), Hase et al. (2002),
Schauber et al. (2006)
CRAMP M.m. IECs DSS↑ Koon et al. (2011), Allen et al. (2012a)
L. monocytogenes↑
Other AMPs RegIIIα or HIP/PAP H.s. Paneth cells - Lasserre et al. (1999), Vaishnava et al. (2008)
RegIIIβ M.m. Paneth cells C. rodentium↑ Willing et al. (2011)
RegIIIγ M.m. Paneth cells Salmonella↑
C. rodentium↑
Lasserre et al. (1999), Vaishnava et al. (2008),
Godinez et al. (2009)
sPLA2 H.s. Paneth cells – Qu et al. (1996)
CCL20/MIP-3α H.s./M.m. IECs EPEC↑
UC↑
CD↑
DSS/TNBS
Kaser et al. (2004), Teramoto et al. (2005),
Katchar et al. (2007), Khan et al. (2008),
Godinez et al. (2009)
Lysozyme C H.s. Paneth cells – Ganz (2004)
Lysozyme C type P M.m. Paneth cells S. typhimurium↓
UC↑
Cross et al. (1988), Salzman et al. (2003),
Ganz (2004)
BPI M.m. IECs UC↑ Schinke et al. (2004)
CD↑
BPI H.s. IECs – Canny et al. (2002)
ANG4 M.m. Paneth cells – Hooper et al. (2003)
RELMβ H.s./M.m. Goblet cells – Artis et al. (2004), Hogan et al. (2006)
H.s., Homo sapiens; M.m., Mus musculus.
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(Geddes et al., 2011). Moreover, NOD1 and NOD2 have been
shown to be crucial for host defense against C. rodentium as
well as Salmonella pathology by triggering an early Th17 response
(Geddes et al., 2011). The mouse cathelicidin CRAMP encoded
by the gene Cnlp also contributes to C. rodentium clearance.
Cnlp−/− mice are more susceptible to C. rodentium infection
as their colonic epithelial extracts have reduced antimicrobial
activity compared to their wild-type littermates (Iimura et al.,
2005). Recently, it was described that microbiota transplantation
from resistant to susceptible wild-type mice before C. rodentium
infection caused delayed pathogen colonization and mortal-
ity due to IL-22 mediated production of RegIIIβ and RegIIIγ
(Willing et al., 2011).
Salmonella enterica serovar typhimurium (S. typhimurium) is
another enteropathogen that causes acute systemic inﬂammation
by using virulence factors to invade the intestinal epithelium (Broz
et al., 2012). During infection, S. typhimurium competes with the
microbiota, changes the bacterial community structure and out-
grows. It was described that S. typhimurium induces the expression
of hBD2, but not the constitutively existing hBD1, in human fetal
intestinal xenografts as well as HT-29 and Caco-2 cell lines in
a FliC (ﬂagella ﬁlament protein)-dependent manner (Bonham
et al., 1999; Ogushi et al., 2001). Mature HD-5 has potent bac-
tericidal activities against S. typhimurium and E. coli infections
(Wehkampet al., 2005; Ishikawa et al., 2010). MMP7deﬁcientmice
lack mature cryptdins; they have an impaired intestinal clearance
of S. typhimurium and Shigella, and thus greater susceptibility
to the infection (Wilson et al., 1999; Atarashi et al., 2011). Actu-
ally, HD-5 transgenic mice are protected against S. typhimurium
infection (Salzman et al., 2003). In a mouse model of Salmonella
colitis, RegIIIβ and RegIIIγ expression is markedly increased
(Godinez et al., 2009). Unlike other pathogens such as Listeria
monocytogenes, Salmonella takes advantage of RegIIIβ/γ secre-
tion, subverts the innate defense and grows over the microbiota
(Godinez et al., 2009; Stelter et al., 2011). Infection of wild-type
mice with S. typhimurium also decreases the expression of crypt-
dins and lysozyme. However, the use of heat killed S. typhimurium
that lacks the Salmonella pathogenicity island 1 (SPI-1) TTSS
and heat killed L. monocytogenes did not affect AMP production
(Salzman et al., 2003).
Shigella, an enteric pathogen closely related to Salmonella, was
found to switch-off LL-37 and hBD1 expression during infection
probably facilitating its invasion and increasing its virulence (Islam
et al., 2001). Similarly, infection of polarized human IECs with S.
ﬂexneri suppressed speciﬁcally the transcription of hBD3 (Speran-
dio et al., 2008). Interestingly, butyrate was found to enhance
LL-37 expression in IECs and treatment of mice with butyrate
decreased the severity of experimental Shigellosis (Raqib et al.,
2006). Several AMPs exert potent antimicrobial activity against
L. monocytogenes including LL-37 and CRAMP (Turner et al.,
1998; Menard et al., 2008). CRAMPwas constitutively expressed in
the IECs of mice early after birth conferring gut homeostasis and
mediating protection against L. monocytogenes infection (Menard
et al., 2008).
There is an intricate yet mutualistic relationship between the
host and its microorganisms within the GI tract. Consequently,
genetic or acquired alterations in the functions of the mucosal
immune barriers may profoundly impact homeostasis and result
in chronic inﬂammatory diseases.
AMPs AND INFLAMMATORY BOWEL DISEASE
Disturbance of intestinal homeostasis results in an altered compo-
sition of the intestinal microbiota or dysbiosis, a hallmark of IBDs.
Crohn’s disease (CD) and ulcerative colitis (UC), the two major
forms of IBD, are characterized by chronic relapsing inﬂammation
of the digestive tract. IBD is amultifactorial disease caused by com-
plex interaction of genetic, microbial, and immunological factors.
Linkage analysis, candidate gene approaches, and genome-wide
association studies have identiﬁed several risk genes for IBD (Bar-
rett et al., 2008; Franke et al., 2010), many of which are involved in
innate immune recognition of bacteria [e.g., NOD2 (Hugot et al.,
2001) and NLRP3 (Villani et al., 2009)] or processing and elim-
ination of bacteria through the autophagy pathway [e.g., IRGM
(Singh et al., 2006) and ATG16L1 (Rioux et al., 2007)]. There is
a paramount role of immune effectors such as PRRs and AMPs
in the intestine. Thus, it is relevant to comprehend whether AMP
secretion is impaired during IBD.
Decreased Paneth cell production of HD-5 and HD-6 was
observed in surgical specimens and biopsies from CD patients
(Wehkamp et al., 2005; Table 1). Nevertheless, it is still contro-
versial whether CD-associated NOD2 mutations contribute to
abnormal defensin secretion (Wehkamp et al., 2004; Simms et al.,
2008). In fact, CD patients have an impaired processing and mat-
uration of HD-5 and administration of exogenous mature HD-5
to DSS-treated mice signiﬁcantly improved the colitis outcome
(Elphick et al., 2008; Ishikawa et al., 2010). Colonic epithelial cells
from UC patients exhibited high mRNA levels of lysozyme, HD-
5, HD-6, and hBD2 compared to cells from healthy controls
(Fahlgren et al., 2003). Similarly, hBD2 expression was reported
in patients with irritable bowel syndrome and in Celiac disease
(Langhorst et al., 2009; Vordenbaumen et al., 2010). In mice,
mBD3 levels are induced following acute DSS-colitis (Rahman
et al., 2011). Moreover, cryptdin- and MMP7-deﬁciency ren-
der mice more susceptible to DSS-induced colitis (Wilson et al.,
1999). hBD1 is the only β-defensin constitutively expressed in
IECs, however its expression is reduced in CD and UC patients
(Wehkamp et al., 2003). Genetic variations in the gene encod-
ing hBD1 were found to be associated with the risk for CD
(Kocsis et al., 2008). LL-37 expression is increased in inﬂamed
and non-inﬂamed mucosa in patients suffering from UC but
not in CD (Schauber et al., 2006). Likewise, CRAMP is induced
during intestinal inﬂammation and Cnlp−/− mice are protected
from DSS-colitis following administration of a synthetic catheli-
cidin (Koon et al., 2011; Allen et al., 2012a). Increasing evidence
show that polymorphisms in BPI are linked to IBD susceptibil-
ity (Akin et al., 2011). BPI levels are greater in biopsies from UC
and CD patients and the protein is a frequent target antigen of
autoantibodies in the sera of IBD patients (Monajemi et al., 1996;
Haapamaki et al., 1999; Schinke et al., 2004). Although CCL20 is
produced in normal and inﬂamed colon tissues, its expression
is signiﬁcantly higher in biopsies from UC and CD patients as
well as in peripheral blood mononuclear cells from UC patients
(Kaser et al., 2004; Fujimaki et al., 2005). Finally,CCL20 is similarly
increased in mice following DSS- and TNBS-induced colitis;
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hence neutralizing its expression with antibodies is sufﬁcient
to reduce the inﬂammatory outcome (Teramoto et al., 2005;
Katchar et al., 2007).
CONCLUSION
Over the past decade our knowledge of the AMPs as immune
effectors at the intestinal epithelial interface has increased expo-
nentially. Their importance in health and disease has only recently
been appreciated and our understanding of their regulatory mech-
anisms remains at an early stage. AMPs possess pleiotropic
functions to not only eradicate microbes in the GI tract but also
control homeostasis and host immunity. AMPs promote innate
and adaptive immune responses to invading microbes through
the recruitment and activation of leukocytes via their interaction
with chemokine and formyl peptide receptors. Dysbiosis and alter-
ations in intestinal microbiota are essential for the development
of IBD pathophysiology and emerging evidence points to a pos-
sible central role for AMPs in determining the composition of
these microbes. Several mechanisms have been hypothesized to
explain how AMPs modulate antimicrobial immunity in the gut
barrier. However, many more questions remain to be addressed.
How AMPs interact with the commensals and help maintaining a
functional gut immune barrier? How the presence of the micro-
biota is affecting the production of these effector molecules? Are
PRRs (TLRs and NLRs) the sole receptors to induce their expres-
sion? Another open question is how the chemotactic properties
of AMPs play a role in the response against microbial infections
and how they bridge innate and adaptive immunity? Better under-
standing of the mechanisms is expected to open new AMP-based
therapeutic avenues to battle infections and strategies for IBDs.
Future studies will focus on the regulatory mechanisms that main-
tain appropriate expression of these antimicrobial factors, and will
provide new insights into the role of AMPs in intestinal home-
ostasis and in the composition of the intestinal microbiota during
health and disease.
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